BioCentury | Sep 28, 2019
Company News

Management tracks: Bourla to succeed Read as Pfizer chair; plus Phathom, OnKure, Forma, Beam, Noven, Cerebral, Alpha Tau and InsightRX

...Brian Riley as SVP, technical operations. He was VP, operations at Catalent Inc. (NYSE:CTLT). The Noven Pharmaceuticals Inc....
...as CEO, effective Oct. 1. He succeeds Jeff Mihm, who is resigning. Higo has been Noven’s...
BioCentury | Jul 11, 2019
Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

...director at life sciences consultancy Locust Walk Partners, where he continues as partner emeritus. The Noven Pharmaceuticals Inc....
BioCentury | Sep 12, 2016
Clinical News

Asenapine maleate transdermal patch: Phase III started

...Hisamitsu’s Noven Pharmaceuticals Inc. subsidiary began a double-blind, placebo-controlled, international Phase III trial to evaluate 2 dose levels...
BioCentury | Feb 23, 2015
Company News

Hisamitsu Pharmaceutical Co. Inc sales and marketing update

...Hisamitsu’s Noven Pharmaceuticals Inc. subsidiary launched 0.025 mg/day Minivelle estradiol transdermal system in the U.S. to prevent postmenopausal...
BioCentury | Oct 13, 2014
Clinical News

Minivelle regulatory update

...FDA approved an sNDA from Hisamitsu's Noven Pharmaceuticals Inc. subsidiary for Minivelle estradiol transdermal patch to prevent postmenopausal...
...low dose. Minivelle is approved to treat moderate to severe vasomotor symptoms due to menopause. Noven...
BioCentury | Sep 8, 2014
Company News

Noven, Novartis deal

...Japan)and Novartis dissolved Vivelle Ventures LLC, a JV formed in 1998 between Novartis and Hisamitsu's Noven Pharmaceuticals Inc....
...was formed to market Noven's Vivelle estrogen replacement therapy patch in the U.S. Hisamitsu acquired Noven...
...an estradiol transdermal system marketed to treat symptoms of menopause and prevent postmenopausal osteoporosis, and Noven...
BioCentury | Jul 21, 2014
Company News

Hisamitsu, ANI Pharmaceuticals deal

...ANI acquired from Hisamitsu’s Noven Therapeutics LLC subsidiary the NDA for Lithobid , an extended-release formulation...
...formulation of lithium carbonate for bipolar disorder, for an upfront cash payment of $11 million. Noven...
BioCentury | May 26, 2014
Company News

Hisamitsu neurology, inflammation, endocrine/metabolic news

...in Vietnam, Indonesia and Beijing, China, and expand the use of production facilities of its Noven Pharmaceuticals Inc....
BioCentury | May 5, 2014
Clinical News

HP-3070: Phase I started

...Hisamitsu's Noven Pharmaceuticals Inc. subsidiary began a U.S. Phase I trial to evaluate HP-3070 in patients with schizophrenia...
BioCentury | Apr 28, 2014
Company News

Endo, Hisamitsu, Teikoku Seiyaku, TWi Pharmaceuticals neurology news

...Hisamitsu's Noven Pharmaceuticals Inc. subsidiary and TWi reached separate settlements with Endo and Teikoku on patent litigation related...
...District Court for the District of Delaware in 2012 alleging that an ANDA submitted by Noven...
...and the '529 patent is set to expire on Oct. 27, 2015. The settlement allows Noven...
Items per page:
1 - 10 of 321
BioCentury | Sep 28, 2019
Company News

Management tracks: Bourla to succeed Read as Pfizer chair; plus Phathom, OnKure, Forma, Beam, Noven, Cerebral, Alpha Tau and InsightRX

...Brian Riley as SVP, technical operations. He was VP, operations at Catalent Inc. (NYSE:CTLT). The Noven Pharmaceuticals Inc....
...as CEO, effective Oct. 1. He succeeds Jeff Mihm, who is resigning. Higo has been Noven’s...
BioCentury | Jul 11, 2019
Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

...director at life sciences consultancy Locust Walk Partners, where he continues as partner emeritus. The Noven Pharmaceuticals Inc....
BioCentury | Sep 12, 2016
Clinical News

Asenapine maleate transdermal patch: Phase III started

...Hisamitsu’s Noven Pharmaceuticals Inc. subsidiary began a double-blind, placebo-controlled, international Phase III trial to evaluate 2 dose levels...
BioCentury | Feb 23, 2015
Company News

Hisamitsu Pharmaceutical Co. Inc sales and marketing update

...Hisamitsu’s Noven Pharmaceuticals Inc. subsidiary launched 0.025 mg/day Minivelle estradiol transdermal system in the U.S. to prevent postmenopausal...
BioCentury | Oct 13, 2014
Clinical News

Minivelle regulatory update

...FDA approved an sNDA from Hisamitsu's Noven Pharmaceuticals Inc. subsidiary for Minivelle estradiol transdermal patch to prevent postmenopausal...
...low dose. Minivelle is approved to treat moderate to severe vasomotor symptoms due to menopause. Noven...
BioCentury | Sep 8, 2014
Company News

Noven, Novartis deal

...Japan)and Novartis dissolved Vivelle Ventures LLC, a JV formed in 1998 between Novartis and Hisamitsu's Noven Pharmaceuticals Inc....
...was formed to market Noven's Vivelle estrogen replacement therapy patch in the U.S. Hisamitsu acquired Noven...
...an estradiol transdermal system marketed to treat symptoms of menopause and prevent postmenopausal osteoporosis, and Noven...
BioCentury | Jul 21, 2014
Company News

Hisamitsu, ANI Pharmaceuticals deal

...ANI acquired from Hisamitsu’s Noven Therapeutics LLC subsidiary the NDA for Lithobid , an extended-release formulation...
...formulation of lithium carbonate for bipolar disorder, for an upfront cash payment of $11 million. Noven...
BioCentury | May 26, 2014
Company News

Hisamitsu neurology, inflammation, endocrine/metabolic news

...in Vietnam, Indonesia and Beijing, China, and expand the use of production facilities of its Noven Pharmaceuticals Inc....
BioCentury | May 5, 2014
Clinical News

HP-3070: Phase I started

...Hisamitsu's Noven Pharmaceuticals Inc. subsidiary began a U.S. Phase I trial to evaluate HP-3070 in patients with schizophrenia...
BioCentury | Apr 28, 2014
Company News

Endo, Hisamitsu, Teikoku Seiyaku, TWi Pharmaceuticals neurology news

...Hisamitsu's Noven Pharmaceuticals Inc. subsidiary and TWi reached separate settlements with Endo and Teikoku on patent litigation related...
...District Court for the District of Delaware in 2012 alleging that an ANDA submitted by Noven...
...and the '529 patent is set to expire on Oct. 27, 2015. The settlement allows Noven...
Items per page:
1 - 10 of 321